 |
|
|
| |
Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/r) plus 2 NRTIs in second-line treatment - 48-week data from the DAWNING Study
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
M. Aboud1, R. Kaplan2, J. Lombaard3, F. Zhang4, J. Hidalgo5, E. Mamedova6, M. Losso7, P. Chetchotisakd8, C. Brites9, J. Sievers1, D. Brown10, J. Hopking11, M. Underwood12, M.C. Nascimento1, M. Gartland12, K. Smith12
Institutions
1ViiV Healthcare, Brentford, United Kingdom, 2Desmond Tutu HIV Foundation, Cape Town, South Africa, 3Josha Research, Bloemfontein, South Africa, 4Beijing Ditan Hospital, Beijing, China, 5VIA LIBRE, Lima, Peru, 6Kiev AIDS Centre, Kiev, Ukraine, 7Hospital J M Ramos MejIa, Buenos Aires, Argentina, 8Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand, 9Federal University of Bahia, Salvador, Brazil, 10ViiV Healthcare, Abbotsford, Australia, 11GlaxoSmithKline, Uxbridge, United Kingdom, 12ViiV Healthcare, Research Triangle Park, United States
|
| |
|
|
|
|
|
